Helius Medical enters $1.95M ATM equity offering with Roth Capital

Solana Co

Company signed Sales Agreement with Roth Capital to sell up to $1.95M of Class A common stock at market prices.
Roth Capital will receive 3.0% commission on gross proceeds from any sales under the at-the-market offering.
Offerings will be made under an existing S-3 registration statement effective May 26, 2023.
Company is not obligated to sell any shares; either party may suspend or terminate the offering.
Net proceeds are expected to be used for general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Solana Co entered into Sales Agreement with Roth Capital Partners, LLC valued at up to $1.95 million (effective 2023-06-23).

Action: entry
Agreement: atm program
Counterparty: Roth Capital Partners, LLC
Value: up to $1.95 million
Effective: 2023-06-23

Exact text from the filing

On June 23, 2023, Helius Medical Technologies, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Roth Capital Partners, LLC, as agent (the “Sales Agent”). Pursuant to the Sales Agreement, the Company may offer and sell up to $1.95 million in shares of Class A common stock, par value $0.001 per share (the “Shares”), from time to time through the Sales Agent.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Solana Co filing history →

Source: SEC EDGAR

accession 0001104659-23-074256

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.